Our team

Associate Professor Dragana Protic, MD, PhD

Education (in chronological order)

Undergraduate

Graduate

Postgraduate

Postdoctoral

Professional positions held

Courses taught and other services provided to students and the home institution

Teaching assignments

Organization of Continual Medical Education (CME) and conference in the field of Fragile X–associated disorders

Publications

Peer–reviewed publications

  1. Aishworiya R, Protic D, Hagerman R. Autism spectrum disorder in the fragile X premutation state: possible mechanisms and implications. J Neurol. 2022 Sep;269(9):4676-4683
  2. Budimirovic DB, Protic DD, Delahunty CM, Andrews HF, Choo TH, Xu Q, Berry-Kravis E, Kaufmann WE; FORWARD Consortium. Sleep problems in fragile X syndrome: Cross-sectional analysis of a large clinic-based cohort. Am J Med Genet A. 2022;188(4):1029-1039.
  3. Protic DD, Aishworiya R, Salcedo-Arellano MJ, Tang SJ, Milisavljevic J, Mitrovic F, Hagerman RJ, Budimirovic DB. Fragile X Syndrome: From Molecular Aspect to Clinical Treatment. Int J Mol Sci. 2022;23(4):1935.
  4. Protic D, Salcedo-Arellano MJ, Stojkovic M, Saldarriaga W, Ávila Vidal LA, Miller RM, Tabatadze N, Peric M, Hagerman R, Budimirovic DB. Raising Knowledge and Awareness of Fragile X Syndrome in Serbia, Georgia, and Colombia: A Model for Other Developing Countries? Yale J Biol Med. 2021;94(4):559-571.
  5. Budimirovic DB, Schlageter A, Sadic-Filipovic S, Protic D, et al. A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients With Neurobehavioral Assessments. Brain Sci 2020;10(10):E694.
  6. Aydin EY, Schneider A, Protic D, Wang JY, Martínez-Cerdeño V, Tassone F, Tang HT, Perlman S, Hagerman RJ. Rapidly Progressing Neurocognitive Disorder in a Male with FXTAS and Alzheimer's Disease. Clin Interv Aging. 2020;15:285-292
  7. Kim K, Hessl D, Randol JL, Espinal GM, Schneider A, Protic D, et al. Association between IQ and FMR1 protein (FMRP) across the spectrum of CGG repeat expansions. PLoS One. 2019;14(12):e0226811.
  8. Protic D, Salcedo-Arellano MJ, Dy JB, Potter LA, Hagerman RJ. New Targeted Treatments in Fragile X Syndrome. Curr Pediatr Rev. 2019 doi: 10.2174/1573396315666190625110748.
  9. Protic D, Aydin EY, Tassone F, Tan MM, Hagerman RJ, Schneider A. Cognitive and behavioral improvement in adults with fragile X syndrome treated with metformin-two cases. Mol Genet Genomic Med. 2019;e745. doi: 10.1002/mgg3.745.
  10. Protic D, Kaluzhny P, Tassone F, Hagerman RJ. Prepubertal Metformin Treatment in Fragile X Syndrome Alleviated
  11. Macroorchidism: A Case Study. Advances in Clinical and Translational Research 2019;3(1):1-5
  12. Protic D, Budimirovic D. Fragile X Gene Premutation: To Recognize Early and Treat Neuropsychiatric Problems. J Mol Genet Med 2019, 13:1. DOI: 10.4172/1747-0862.1000391.
  13. Budimirovic DB, Cvjetkovic S, Bukumiric Z, Duy PQ, Protic D. Fragile X-Associated Disorders in Serbia: Baseline Quantitative and Qualitative Survey of Knowledge, Attitudes and Practices Among Medical Professionals. Front Neurosci 2018;12:652. doi: 10.3389/fnins.2018.00652.
  14. Hagerman RJ, Protic D, Rajaratnam A, Salcedo-Arellano MJ, Aydin EY, Schneider A. Fragile X-associated Neuropsychiatric Disorders (FXAND) Front Psychiatry 2018;9:564 doi: 10.3389/fpsyt.2018.00564
  15. Zafarullah M, Tassone F, Protic D, Budimirovic D. Fragile X-Associated Tremor/Ataxia Syndrome (FXTAS). EkoMed Plus 2018;42:16-18.
  16. Budimirovic, D.B., Protic, D., Toma, A.E. (2017). Fragile X Syndrome: Leading the way as most common monogenic form of autism spectrum disorder and the most translated among neurodevelopmental disorders in clinical trials. J Clin Gen and Genomics Nov 2017 1(1), 1-2.
  17. Budimirovic D, Protic D. FMR1 gene mutations cause neurodevelopmental-degenerative disorders: Importance of fragile X testing in Serbia. Vojnosanit Pregl 2016;72(12):1089–1093. doi: 10.2298/VSP161006315B
  18. Protic D, Budimirovic D. From idea to implementation: what does mean the development of new drug? The development of drugs for the fragile X syndrome (FXS) EkoMed Plus 2016;29:18-22.
  19. Budimirovic D., Protic D (2016). Drugs Development and Fragile X Syndrome Translational Success Story. MedPodml 67(4):14-18.doi:10.5937/mp67-12697.
  20. Protic D, Pejovic A, Djukanovic N, Toskovic B, Zdravkovic M, Todorovic Z. Analysis of the third- and fourth-generation cephalosporin use for the treatment of infections caused by Gram-negative bacteria in hospital settings. Int J Clin Pract 2016;70(12):1033-1040. PMID: 28032422
  21. Todorovic ZM, Djukanovic NinaB, Obradovic SD, Protic DD, Ostojic MC. Clopidogrel-Statin Interaction: a Missing Links Hospital Pharmacology 2016; 3(2):395-401.
  22. Djukanovic N, Todorovic Z, Zamaklar-Trifunovic D, Protic D, Dzudovic B, Ostojic M, Obradovic S. Sustained increase in platelet aggregation after the cessation of clopidogrel. Clin Exp Pharmacol Physiol 2016;43(2):161-5. PMID: 26515635
  23. Protic D, Vujasinović-Stupar N, Bukumirić Z, Pavlov-Dolijanović S, Baltić S, Mutavdžin S, Marković-Denić L, Zdravković M, Todorović Z. Profile of rheumatology patients willing to report adverse drug reactions: bias from selective reporting. Patient Prefer Adherence 2016;10:115-21. PMID: 26893547, PMCID: PMC4745948
  24. Mugoša S, Djordjević N, Bukumirić Z, Djukanović N, Cukić J, Radosavljević I, Baskić D, Protic D, Zdravković M, Todorović Z. PREDICT score and CYP2C19 polymorphism independently predict lack of efficacy of clopidogrel in cardiology patients. Clin Exp Pharmacol Physiol 2016;43(3):379-81. PMID: 26699839
  25. Protic D, Pejovic A, Andjelkovic D, Djukanovic N, Savic D, Piperac P, Markovic Denic L, Zdravkovic M, Todorovic Z. Nosocomial Infections Caused by Acinetobacter baumannii: Are We Losing the Battle? Surg Infect 2016;17(2):236-42. PMID: 26885722
  26. Mugoša S, Djordjević N, Djukanović N, Protic D, Bukumirić Z, Radosavljević I, Bošković A, Todorović Z. Factors affecting the development of adverse drug reactions to β-blockers in hospitalized cardiac patient population. Patient Prefer Adherence 2016;10:1461-9. PMID: 27536078
  27. Protic D, Savic D, Andjelkovic D, Djukanovic N, Zdravkovic M, Djurasevic SF, Todorovic Z. Nosocomial coagulase-negative staphylococci in Belgrade: between Scylla and Charybdis. J Infect Dev Ctries 2016;10(9):907-912. PMID: 27694722
  28. Mugosa S, Bukumirić Z, Kovacević A, Bosković A, Protic D, Todorović Z. Adverse drug reactions in hospitalized cardiac patients: characteristics and risk factors. Vojnosanit Pregl 2015;72(11):975-81. PMID:26731971
  29. Obradovic S, Djukanovic N, Todorovic Z, Markovic I, Zamaklar-Trifunovic D, Protic D, Ostojic M. Men with lower HDL cholesterol levels have significant increment of soluble CD40 ligand and high-sensitivity CRP levels following the cessation of long-term clopidogrel therapy. J Atheroscler Thromb 2015;22(3):284-92. PMID: 25273829
  30. Protic D, Radunović N, Spremović-Rađenović S, Živanović V, Heinle H, Petrović A,  Gojković-Bukarica L. The Role of Potassium Channels in the Vasodilatation Induced by Resveratrol and Naringenin in Isolated Human Umbilical Vein. Drug Dev Res 2015; PMID: 25619904 (in press).
  31. Todorovic Z, Protic D. Bioethical Issues in the Development of Biopharmaceuticals. Filozofija i društvo 2012;XXIII(4):49-56.
  32. Djukanovic N, Todorovic Z, Obradovic S, Njegomirovic S, Zamaklar-Trifunovic D, Protic D, Ostojic M. Clopidogrel cessation triggers aspirin rebound in patients with coronary stent. J Clin Pharm Ther 2014;39(1):69-72. PMID: 24286218
  33. Protic D, Baltic S, Vujasinovic-Stupar Nada, Pavlov-Dolijanovic S, Mugosa S, Todorovic Z. A case of myositis with immunological background associated with statin use. CEJM 2014; 9(5):619-624.
  34. Protic D, Beleslin-Čokić B, Spremović-Rađenović S, Radunović N, Heinle H, Sćepanović R, Gojković Bukarica L. The different effects of resveratrol and naringenin on isolated human umbilical vein: the role of ATP-sensitive K⁺ channels. Phytother Res 2014; 28(9):1412-8. PMID: 24638940
  35. Protic D, Todorovic Z, Gojkovic-Bukarica L. Potassium channels as drug targets in therapy of cardiovascular deseases: 25 years later. Sanamed 2013; 8(1):71-79.
  36. Protic D, Beleslin-Čokić B, Novaković R, Kanjuh V, Heinle H, Sćepanović R, Gojković-Bukarica L. Effect of wine polyphenol resveratrol on the contractions elicited electrically or by norepinephrine in the rat portal vein. Phytother Res 2013; 27(11):1685-93. PMID: 23296904
  37. Bukarica LG, Protic D, Kanjuh V, Heinle H, Novakoviĉ R, Scepanovic R. Cardiovascular effects of resveratrol. Vojnosanit Pregl 2013;70(12):1145-50. PMID: 24450260
  38. Novakovic R, Milovanovic S, Protic D, Djokic J, Heinle H, Gojkovic-Bukarica L. The effect of potassium channel opener pinacidil on the non-pregnant rat uterus.  Basic Clin Pharmacol Toxicol 2007;101(3):181-6. PMID: 17697038

Book chapters

  1. Hagerman R, Protic D, Berry-Kravis E. Medical, Psychopharmacological and Targeted Treatment for FXS. In: Fragile X Syndrome and Premutation Disorders: New Developments and Treatments: A Primer for Clinicians and Families (Hagerman & Hagerman, edts.) (in publishing)
  2. Protic D,Samardzic J. Effects of drugs and psychoactive substances on the nervous system. In: Todorović Z, Turza K, Drulović J (eds). Neuroethics [in Serbian]. Belgrade: University of Belgrade, School of Medicine, 2017.
  3. Dukanovic N, Todorovic Z, Protic D. Placebo and neuroethics. In: Todorović Z, Turza K, Drulović J (eds). Neuroethics [in Serbian]. Belgrade: University of Belgrade, School of Medicine, 2017.
  4. Samardzic J, Protic D, Obradovic D. Research, writing and presentation of research results: Ethical dilemma and problems in neuropharmacology. In: Todorović Z, Turza K, Drulović J (eds). Neuroethics [in Serbian]. Belgrade: University of Belgrade, School of Medicine, 2017.
  5. Todorovic Z, Protic D. Neuroethics in drug development. In: Todorović Z, Turza K, Drulović J (eds). Neuroethics [in Serbian]. Belgrade: University of Belgrade, School of Medicine, 2017.
  6. Protic D. Parenteral drugs administration. In: Prostran M (editor). Clinical Pharmacology [in Serbian]. Beograd: Belgrade University School of Medicine; 2012.
  7. Protic D. Case reports: antiasthmatic drugs use. In:  Prostran M (editor). Clinical Pharmacology [in Serbian]. Beograd: Belgrade University School of Medicine; 2012.
  8. Protic D. Case reports: antidiabetic drugs use. In: Prostran M (editor). Clinical Pharmacology [in Serbian]. Beograd: Belgrade University School of Medicine; 2012.
  9. Protic D. Dose–response relationship. In: Todorovic Z (editor). Practicum of Pharmacology [in Serbian]. Beograd: Belgrade University School of Medicine; 2012.
  10. Protic D. The effects of adrenergic and anti-adrenergic drugs. In: Todorovic Z (editor). Practicum of Pharmacology [in Serbian]. Beograd: Belgrade University School of Medicine; 2012.
  11. Protic D. Anaphylactic reaction to drugs and anaphylaxis treatment and management. In: Todorovic Z (editor). Practicum of Pharmacology [in Serbian]. Beograd: Belgrade University School of Medicine; 2012.
  12. Protic D. Antiseptic and disinfectant use. In: Todorovic Z (editor). Practicum of Pharmacology [in Serbian]. Beograd: Belgrade University School of Medicine; 2012.
  13. Protic D. Drugs affecting respiratory system. In: Todorovic Z (editor). Practicum of Pharmacology [in Serbian]. Beograd: Belgrade University School of Medicine; 2012.
  14. Protic D. Drugs affecting smooth muscle in gastrointestinal truck. In: Todorovic Z (editor). Practicum of Pharmacology [in Serbian].. Beograd: Belgrade University School of Medicine; 2012.

Meeting abstracts

  1. Budimirovic DB, Andrews H, Brown J, Protic D, Kaufmann WE. Sleep problems in Fragile X syndrome: Cross-sectional analysis of a large clinic-based cohort. 17th NFXF International Fragile X Conference-Virtual Series, јул 22, 2020
  2. Budimirovic DB, Protic D, Schlageter A, Sadic-Filipovic S, Clark Z, Brown J, et al. Genotype-phenotype associations in female FMR1 premutation: three case reports, one had an early menopause”, The 39th National Congress of the South African Society of Obstetricians& Gynaecologists, Central Drakensberg, South Africa.
  3. 3.Budimirovic DB, Schlageter A, Bram E, Sadic-Filipovic S, Nicholson K, Culp K, Javanmard K3, Protic D, Sharp K, Adayev T, LaFauci G, Dobkin C, Brown T, Zhou L, Berry-Kravis E, Findling RL, Latham GJ. Genotype-phenotype associations in male and female FMR1 premutation cases. 4th International Conference on FMR1 premutation: Rotterdam Sept 25-28, 2019.
  4. Budimirovic DB, Protic D. FMR1 gene premutation: A case-series study in pediatric population with Fragile X-associated Neuropsychiatric Disorders (FXAND). 4th International Conference on FMR1 premutation: Rotterdam Sept 25-28, 2019.
  5. Budimirovic D, Protic D, Thomas E, Cvijetkovic S. Pharmacotherapy of Behavior in FXS Patients with and without Co-morbid Autism Spectrum Disorder: A 14-year Cross-Sectional Retrospective Study. 16th International Fragile X Conference. Cincinnati, Ohio. July 11-15, 2018.
  6. Budimirovic DB, Bukumiric Z, Cvetkovic S, Phan D, Protic D. Fragile X-associated disorders in Serbia: baseline quantitative and qualitative survey of knowledge, attitudes and practices among medical professionals. Proceedings of the Third International Conference of FMR1Premutation in Sept of 2017, Jerusalem, Israel.
  7. Protic D, Helmut H, Radunovic N, Novakovic R, Scepanovic R, Gojkovic-Bukarica L. The antivasoconstrictor effect of naringenin on the isolated rat portal vein. The 47th Annual Scientific Meeting of the European Society for Clinical mInvestigation; 2013; Albufeira, Portugal [meeting]
  8. Novakovic R, Beleslin-Cokic B, Ilic B, Radunovic N, Protic D, Heinle H, Scepanovic R, Gojkovic-Bukarica L. The relaxation of pregnant human myometrium by natural polyphenol resveratrol. Resources of Danubian region: The possibility of cooperation and utilization; 2013; Belgrade, Serbia. [meeting]
  9. Protic D, Novakovic R, Spremovic-Radjenovic S, Radunovic N, Heinle H, Gojkovic-Bukarica L. The effect of resveratrol on the human umbilical vein. Resources of Danubian region: the possibility of cooperation and utilization; 2013; Belgrade, Serbia [meeting]
  10. Novakovic R, Beleslin-Cokic B, Ilic B, Radunovic N, Protic D, Helmut H, Scepanovic R, Gojkovic-Bukarica L. Contribution of different K+ channels in the effects of resveratrol on the phasic and tonic contractions of non-pregnant rat uterus. The 47th Annual Scientific Meeting of the European Society for Clinical nvestigation; 2013; Albufeira, Portugal [meeting]
  11. Gojkovic-Bukarica L, Markovic-Lipkovski J, Cirovic S, Novakovic R, Protic D, Kanjuh V, Helmut H. Relaxation of rat renal artery of diabetic rat by resveratrol: involvement of smooth muscle voltage-sensitive potassium channels. The 47th Annual Scientific Meeting of the European Society for Clinical Investigation; 2013; Albufeira, Portugal. [meeting]
  12. Todorovic Z, Basa M, Protic D, Mugosa S. Attitudes towards adverse drug reactions risk among physicians and university students The 47th Annual Scientific Meeting of the European Society for Clinical Investigation; 2013; Albufeira, Portugal. [meeting]
  13. Mugosa S, Bukumiric Z, Protic D, Todorovic Z. Influence of pharmacological education on awareness of the risk of adverse drug reactions the 11th Conference of the European Association for Clinical Pharmacology and Therapeutics; 2013; Geneva, Switzerland. [meeting]
  14. Protic D, Novakovic R, Spremovic-Radjenovic S, Radunovic N, Helmut H, Gojkovic-Bukarica L. Wine polyphenol resveratrol relaxes human umbilical vein. The 46th Annual Scientific Meeting of the European Society for Clinical Investigation; 2012; Budapest, Hungary [meeting]
  15. Protic DD, Spremovic-Radjenovic SS, Radunovic NV, Kanjuh VI, Helmut H, Gojkovic-Bukarica LC. Potassium Channels Are Involved in the Vasodilatation of Human Umbilical Vein by  Resveratrol. Abstracts of the 79th EAS Congress; 2011; Milan, Italy [meeting]
  16. Protic DD, Novakovic RB, Spremovic-Radjenovic SS, Radunovic NV, Helmut H, Gojkovic-Bukarica LC. The Effect of Resveratrol on the Human Umbilical Vein Without Endothelium. The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2011; Budapest, Hungary [meeting]
  17. Ivkovic BM, Vladimirov SoteM, Dragan O, Protic DD, Novakovic RB, Cvejic JM, Kanjuh VI, Gojkovic-Bukarica LC. Novel Propafenone Analogs Have Antiarrhythmic Effect The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2011; Budapest, Hungary [meeting]
  18. Novakovic RB, Protic DD, Radunovic NV, Heinle H, Cvejic JM, Gojkovic-Bukarica LC. Resveratrol Relaxes Smooth Muscles of Rat Uterus. The 10th Congress of the European Association for Clinical Pharmacology and Therapeutics; 2011; Budapest, Hungary [meeting]
  19. Gojkovic-Bukarica LC, Markovic-Lipkovski JZ, Protic DD, Heinle H. Wine polyphenol resveratrol induces relaxation of rat renal artery by activation  of voltage-sensitive potassium channels. The 18th Scientific Meeting of the European Society of Hypertension and the 22nd Scientific Meeting of the International Society of Hypertension; 2008 [meeting]
  20. Gojkovic Bukarica L, Novakovic A, Kanjuh V, Protic D, Cvejic J, Heinle H.Endothelium-dependent relaxation of isplated rat mesenteric artery induced by resveratrol. Neuue Aspekte der Arterioskleroseforschung-Beitrage zur 22. Jahrestagung der Deutschen Gesellschaft fur Arterioskleroseforschung; 2008 [meeting]

Other professional activities

Ongoing research support

Completed research support

Fragile X clinic

Thanks to the efforts of Dr. Protic, a Fragile X Clinic was established in Belgrade, Serbia in June 2018. The Fragile X Clinic is located at the Institute for Health Protection of Mother and Child of Serbia at the children’s hospital which is a part of the Faculty of medicine University of Belgrade. It is the first Fragile X Clinic in the South–East Europe and has the opportunity of serving the entire region. In other words, Belgrade is the centre of fragile X in this part of Europe. The clinic provides newest treatment for patients with FXS along with cutting–edge management of these individuals.

Fragile X Society — Balkans

Dr. Protic also established Fragile X Society — Balkans in Serbia in March 2019. The Society is non–governmental and non–profit society established with the main objective to organize medical education, research activities and health promotion in the field of fragile X. The members of the Society are medical professionals, as well as parents and families of children with FXS from Serbia and whole region. Currently, she is President of the Society.

Membership and activities in professional associations

Community service

© 2024 POLYFRAX_Drosophila Project • Web design & development Tacit LLC Sombor